Full Text View
Tabular View
Study Results
Related Studies
Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.
This study has been completed.
Study NCT01011387   Information provided by Molnlycke Health Care AB

First Received on November 4, 2009.   Last Updated on March 20, 2012   History of Changes

November 4, 2009
March 20, 2012
January 2010
July 2010   (final data collection date for primary outcome measure)
Mean Change in Wound Area. [ Time Frame: From baseline to maximum 4 weeks ] [ Designated as safety issue: No ]
Measured by tracing of wound and measured by planimeter.
To assess wound healing and granulation tissue formation when using the Avance™ NPWT system [ Time Frame: 3 times per week during 4 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01011387 on ClinicalTrials.gov Archive Site
 
  • To investigate the pain level at dressing removal [ Time Frame: at each visit during 4 weeks ] [ Designated as safety issue: No ]
  • To visually check exudate removal [ Time Frame: at each visit during 4 weeks ] [ Designated as safety issue: No ]
  • To investigate the ease of use for the subject and care giver when using the Avance™ NPWT system [ Time Frame: after 4 weeks ] [ Designated as safety issue: No ]
 
 
 
Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.
A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a NPWT (Negative Pressure Wound Therapy) System to be Used in the Treatment of Diabetic Foot Ulcers (DFUs) Including Post Amputation Wounds Associated With Diabetes.

Primary objective

  • To assess wound healing and granulation tissue formation when using the NPWT system

Secondary objectives

  • To investigate the pain level at dressing removal
  • To visually check exudate removal
  • To investigate the ease of use for the subject and care giver when using the NPWT system

The investigation is designed as a prospective, open, non-controlled clinical investigation.

Wounds to be treated under this protocol should be Diabetic foot ulcers (DFUs) or post amputation wounds associated with diabetes in hospitalized subjects or subjects treated at home. One ulcer or post amputation wound per subject will be treated for a maximum duration of 4 weeks. All subjects will receive negative pressure treatment with the NPWT system, -120 mm Hg.

In total, 10-15 subjects at two sites will be enrolled provided that they fulfill all the inclusion criteria and none of the exclusion criteria and have signed and dated a written informed consent.

The subjects will be consecutively allocated to a specific subject identification code and the recruitment will be competitive.

The primary variable wound healing and granulation tissue formation will be assessed by digital planimeter, digital photography and visual estimation.

Pain level and subject/investigator convenience will be assessed by convenience surveys.

An evaluable subject is defined as a subject completing the investigation with 4 weeks of treatment, a subject healed before 4 weeks of treatment or if the investigator judge that the wound has adequately responded on NPWT before 4 weeks and that continued treatment can be made with alternative treatment.

Interventional
 
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Diabetes
  • Foot Ulcers
  • Procedure: NPWT System
    Dressing change 3 times per week
  • Device: NPWT system
    3 dressing changes/week for maximum 4 weeks.
NPWT system
Negative pressure wound therapy
Interventions:
  • Procedure: NPWT System
  • Device: NPWT system
 

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diabetic foot ulcers (DFUs) including post amputation wounds associated with diabetes suitable for Negative Pressure Wound Therapy according to the investigator's judgment
  2. 1 cm2 ≤ Wound size ≤ 200 cm2
  3. Male or female, 18 years and above
  4. Signed Informed Consent Form
  5. Subject understands the written subject Information

Exclusion Criteria:

  1. Need for frequent dressing changes, i.e.<72 hours between the changes
  2. Dry wounds
  3. Critical ischemia (for wound healing) according to investigator's judgement
  4. Malignancy in the wound and/or wound margin
  5. Target ulcer previous not successfully treated with NPWT within 48 hours
  6. Poorly controlled diabetes according to investigators judgement.
  7. Osteomyelitis which has been left untreated
  8. Infection which has been left untreated
  9. Unexplored fistula
  10. > 10% surface area necrotic tissue with eschar present after debridement
  11. High risk for bleeding complications
  12. Exposed major blood vessels, organs or nerves
  13. Current or within 3 months treatment with chemotherapy or irradiation
  14. Known hypersensitivity to the dressing material
  15. Expected technically impossible to seal the film to maintain a vacuum for treatment
  16. Expected non compliance with the Clinical Investigation Plan
  17. Pregnancy
  18. Subjects not suitable for the investigation according to the investigator's judgement
  19. Subjects previously included in this investigation
  20. Subjects included in other ongoing clinical investigation at present or during the past 30 days
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01011387
NPWT 01
No
Molnlycke Health Care AB
Molnlycke Health Care AB
 
Principal Investigator: Gerard Stansby, MD, Prof. Freeman Hospital, Newcastle upon tyne
Molnlycke Health Care AB
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP